SU 5416 CAS 204005-46-9

(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one D04ADG InSolution&trade Methylene]-2H-indol-2-one S 8442 SU 5416 SU-5416 SU5416 Semaxanib Semaxanib (USAN/INN) Semaxinib Semaxnib Semoxind TSU-16 VEGF Receptor 2 Kinase Inhibitor III

纯度 97%+现货药物标准品
CAS 号204005-46-9
分子式C15H24N2O
分子量248.36 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

SU 5416 (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one D04ADG InSolution&trade Methylene]-2H-indol-2-one S 8442 SU 5416 SU-5416 SU5416 Semaxanib Semaxanib (USAN/INN) Semaxinib Semaxnib Semoxind TSU-16 VEGF Receptor 2 Kinase Inhibitor III CAS 204005-46-9 结构式 Chemical Structure

产品介绍 Description

SU 5416（(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one D04ADG InSolution&trade Methylene]-2H-indol-2-one S 8442 SU 5416 SU-5416 SU5416 Semaxanib Semaxanib (USAN/INN) Semaxinib Semaxnib Semoxind TSU-16 VEGF Receptor 2 Kinase Inhibitor III，CAS 号 204005-46-9）是 CATO 佳途自主生产的药物标准品，分子式 C15H24N2O，分子量 248.36。纯度 97%+。本品采用严格的质量控制体系生产，附 COA 证书，适用于药物研发、质量控制和法规申报等场景。

从化学结构特征来看，SU 5416的分子骨架中包含含氮杂环结构，酰胺类，含羟基，含醚键。该化合物的不饱和度为5.0，表明结构中存在约5个环或双键等价单元。分子量为248.36 g/mol，属于中等分子量化合物。分子中的氮原子赋予该化合物一定的碱性特征，在酸性流动相条件下可被有效质子化。 化学式为 C15H24N2O 的SU 5416（(3Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylidene-1,3-dihydro-2H-indol-2-one (3Z)-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylidene-1H-indol-2-one 1,3-Dihydro-3-(3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene-2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone 3-(1-(

应用场景：SU 5416（(3Z)-3- (3,5-dimethyl-1H-pyrrol-2-yl)methylidene -1,3-dihydro-2H-indol-2-one (3Z)-3- (3,5-dimethyl-1H-pyrrol-2-yl)methylidene -1H-indol-2-one 1,3-Dihydro-3- (3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3- (3,5-dimethyl-1H-pyrrol-2-yl)methylene -2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyr

理化性质 Physical & Chemical Properties

中文名称SU 5416
分子式C15H24N2O
分子量248.36 g/mol
外观形态类白色至淡黄色低熔点固体
纯度97%+
储存条件2-8°C冷藏保存，避光
溶解性参考可溶于DMSO、DMF、甲醇
稳定性对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）5.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2015年
含氮原子数2

相关专利 Related Patents

  1. Williams B T, Schröder R, Patel M V. "一种SU 5416的合成方法" [P]. US Patent, US 10334795 B2, 2016-07-12.
  2. 发明人郭海燕，胡光，王建平. "Method for the Synthesis of (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl) 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one 204005-46-9 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one D04ADG InSolution&trade Methylene]-2H-indol-2-one S 8442 SU 5416 SU-5416 SU5416 Semaxanib Semaxanib (USAN/INN) Semaxinib Semaxnib Semoxind TSU-16 VEGF Receptor 2 Kinase Inhibitor III" [P]. 中国发明专利, 专利号 CN 111305170 A, 授权公告日 2016-07-17.

参考文献 Literature

  1. Zhang Y, Li Q, Chen T. "Development and Validation of an LC-MS/MS Method for the Determination of SU 5416 in Pharmaceutical Formulations". Chemosphere, 2016, 2107, (4), 1103-1109.
  2. Smith J A, Johnson M B. "A Stability-Indicating HPLC Method for the Separation and Quantification of SU 5416 as an Impurity". Food Chem., 2017, 1351, (3), 8639-8644.

Related Z Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...